March 3, 2023
Proposed telehealth prescription rules affect testosterone
Proposed DEA rules would provide safeguards for telemedicine consultations by a medical practitioner who has never conducted an in-person evaluation of a patient that result in the prescribing of a controlled medication for that patient. This would affect prescriptions for compounded testosterone, for instance.
However, the proposed telemedicine rules would allow medical practitioners to prescribe 30-day supplies of both Schedule III-V non-narcotic controlled medications and buprenorphine for the treatment of opioid use disorder.
Access the full proposals here and here. The public has 30 days from February 24 to review and comment on the proposals, which DEA will then consider before drafting final regulations.
